Programme Costing of a Physical Activity Programme in Primary Prevention: Should the Costs of Health Asset Assessment and Participatory Programme Development Count?

by Silke B. Wolfenstetter, Bernd Schweikert, Jürgen John
Published 2012-01-01

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

by Susanne Hartz, Christophe Sapin, Bernd Schweikert, Chiara Malmberg, Mercedes Núñez, Tatiana Dilla
Published 2020-08-01